{"id":"other-statin","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver transaminases"},{"rate":"<0.1","effect":"Rhabdomyolysis"},{"rate":"1-3","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking HMG-CoA reductase, statins decrease hepatic cholesterol production and upregulate LDL receptor expression on liver cells, leading to increased clearance of LDL cholesterol from the bloodstream. This mechanism reduces cardiovascular risk by lowering atherogenic lipid levels and may provide additional pleiotropic anti-inflammatory benefits.","oneSentence":"Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:14.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Primary prevention of cardiovascular disease"},{"name":"Secondary prevention of cardiovascular events"}]},"trialDetails":[{"nctId":"NCT07447648","phase":"","title":"Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","startDate":"2026-03","conditions":"Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography","enrollment":52},{"nctId":"NCT05977413","phase":"NA","title":"NOTIFY (New Observations Taking Information From Yesterday)","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2026-03-01","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":""},{"nctId":"NCT04894877","phase":"","title":"ISCHEMIA-EXTEND (Extended Follow-up)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2012-07","conditions":"Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease","enrollment":5391},{"nctId":"NCT05362903","phase":"","title":"A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-28","conditions":"Hypercholesterolemia","enrollment":1871},{"nctId":"NCT06855537","phase":"PHASE4","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-03","conditions":"Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma","enrollment":2190},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT04755413","phase":"NA","title":"The Precision CAD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Coronary Artery Disease","enrollment":276},{"nctId":"NCT04980716","phase":"PHASE3","title":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Non-small Cell Lung Cancer, Cardiovascular Complication","enrollment":524},{"nctId":"NCT01180361","phase":"","title":"Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT02908425","phase":"NA","title":"Cholesterol and Statin in Healthy Adults","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2016-07-08","conditions":"Elevated HMB Excretion","enrollment":13},{"nctId":"NCT06423365","phase":"NA","title":"A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2024-10-24","conditions":"Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases","enrollment":816},{"nctId":"NCT05720156","phase":"","title":"Immunomodulatory Effects of PCSK9 Inhibition","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2024-04-04","conditions":"Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis","enrollment":""},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT05514938","phase":"PHASE2","title":"Polypill in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-30","conditions":"Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease","enrollment":140},{"nctId":"NCT04992065","phase":"PHASE2","title":"A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":267},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT03753555","phase":"PHASE4","title":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-01","conditions":"Stroke, Ischemic, Atherosclerosis, Cerebral","enrollment":100},{"nctId":"NCT06825676","phase":"NA","title":"Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-03","conditions":"Renal Insufficiency, Chronic, Cardiovascular Diseases (CVD)","enrollment":1800},{"nctId":"NCT06031610","phase":"","title":"Revascularization Effect on CSVD Burden in Carotid Artery Stenosis","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2023-06-10","conditions":"Carotid Artery Stenosis, Cerebral Small Vessel Diseases","enrollment":1000},{"nctId":"NCT04022850","phase":"NA","title":"De-implementation of Low-value Pharmacological Prescriptions","status":"COMPLETED","sponsor":"Basque Health Service","startDate":"2022-05-05","conditions":"Inappropriate Prescribing, Implementation Science, Behavioral Sciences","enrollment":348},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT02099123","phase":"PHASE4","title":"A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2015-07","conditions":"Independent Living, Disability Free Survival, Elderly","enrollment":9971},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT04073797","phase":"NA","title":"PET Imaging of Inflammation and Lipid Lowering Study","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2023-03-20","conditions":"Hypercholesterolemia, Hypercholesterolemia, Familial, Atherosclerosis","enrollment":63},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06455488","phase":"","title":"MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry","status":"RECRUITING","sponsor":"CorVita Science Foundation","startDate":"2020-07-20","conditions":"Ventricular Tachycardia","enrollment":130},{"nctId":"NCT04359823","phase":"PHASE1","title":"DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-08-24","conditions":"Actinic Porokeratosis","enrollment":31},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT06074367","phase":"PHASE4","title":"The Impact of Oral Vitamin C in Prevention for Post Operative Atrial Fibrillation (POAF) in Coronary Artery Bypass Surgery (CABG) Patients","status":"UNKNOWN","sponsor":"Helwan University","startDate":"2020-10-13","conditions":"Post Operative Atrial Fibrillation","enrollment":180},{"nctId":"NCT01980823","phase":"EARLY_PHASE1","title":"Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-10","conditions":"Breast Cancer, Breast Tumors, Cancer of Breast","enrollment":23},{"nctId":"NCT03273972","phase":"NA","title":"INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-09-07","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":30},{"nctId":"NCT01471522","phase":"NA","title":"International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-07","conditions":"Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease","enrollment":5179},{"nctId":"NCT05216913","phase":"","title":"Optimising Cardiovascular Health in Endometrial Cancer Survivors","status":"UNKNOWN","sponsor":"University of Manchester","startDate":"2022-02-09","conditions":"Endometrial Cancer, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT05709509","phase":"PHASE4","title":"Effect of Colchicine on MMP-9, NOX2, and TGF-β1 in Myocardial Infarct","status":"UNKNOWN","sponsor":"RSD dr. Soebandi","startDate":"2022-06-01","conditions":"ST Elevation Myocardial Infarction, Colchicine, Cardiac Remodeling, Ventricular","enrollment":148},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT05792293","phase":"PHASE2, PHASE3","title":"Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-06-01","conditions":"Doxorubicin Induced Cardiomyopathy","enrollment":100},{"nctId":"NCT03175367","phase":"PHASE2","title":"Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-10","conditions":"Hypercholesterolemia","enrollment":272},{"nctId":"NCT03837925","phase":"PHASE3","title":"Pharmaco-metabolomic Effects of Statins: METASTATINE","status":"COMPLETED","sponsor":"French Cardiology Society","startDate":"2019-06-13","conditions":"Cardiovascular Diseases","enrollment":120},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT03868007","phase":"NA","title":"Protective Effects of RIC in Elderly With Acute Ischemic Stroke Complicating Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2019-03-10","conditions":"Elderly Patients, Acute Ischemic Stroke, Acute Coronary Syndrome","enrollment":80},{"nctId":"NCT05559307","phase":"PHASE4","title":"Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Ying Gao","startDate":"2022-08-16","conditions":"Ischemic Stroke, Acute","enrollment":20},{"nctId":"NCT05560152","phase":"PHASE2, PHASE3","title":"Analyzing the Pharmacodynamic Substances and the Effects of Yiqihuayu Decotion for Acute Ischemic Stroke (PHYSIS)","status":"UNKNOWN","sponsor":"Ying Gao","startDate":"2022-09-25","conditions":"Ischemic Stroke, Acute","enrollment":15},{"nctId":"NCT04426084","phase":"","title":"Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2020-03-01","conditions":"COVID-19","enrollment":22784},{"nctId":"NCT05307718","phase":"","title":"Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction","status":"UNKNOWN","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-12-15","conditions":"Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs","enrollment":1200},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT01985360","phase":"PHASE4","title":"ISCHEMIA-Chronic Kidney Disease Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01","conditions":"Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases","enrollment":777},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT05007054","phase":"","title":"Long-Term Outcomes in Patients With Three-Vessel Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-05-01","conditions":"Three Vessel Coronary Disease","enrollment":4300},{"nctId":"NCT04359095","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2020-08-18","conditions":"COVID-19","enrollment":650},{"nctId":"NCT02648243","phase":"NA","title":"Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar","status":"COMPLETED","sponsor":"Qatar University","startDate":"2016-03-01","conditions":"Acute Coronary Syndromes","enrollment":373},{"nctId":"NCT03533153","phase":"PHASE1, PHASE2","title":"Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-03-01","conditions":"Myocardial Infarction","enrollment":90},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT01860729","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-13","conditions":"Hypercholesterolemia","enrollment":589},{"nctId":"NCT01715376","phase":"","title":"Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events","status":"COMPLETED","sponsor":"Changchun University of Chinese Medicine","startDate":"2012-03","conditions":"Angina Pectoris, Coronary Artery Disease, Coronary Disease","enrollment":1042},{"nctId":"NCT02963311","phase":"PHASE2","title":"A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2016-12-13","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":9},{"nctId":"NCT02452502","phase":"NA","title":"The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2015-09-02","conditions":"Stroke","enrollment":254},{"nctId":"NCT00367458","phase":"PHASE2","title":"Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10-18","conditions":"HIV","enrollment":24},{"nctId":"NCT02347098","phase":"PHASE3","title":"Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-03-30","conditions":"Acute Coronary Artery Syndrome","enrollment":270},{"nctId":"NCT01524289","phase":"PHASE3","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-03","conditions":"Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial","enrollment":306},{"nctId":"NCT03971019","phase":"PHASE3","title":"Survival Benefits of Statins in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-03-28","conditions":"Breast Cancer Female","enrollment":314},{"nctId":"NCT01252875","phase":"NA","title":"Treat Stroke to Target","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-03-15","conditions":"Ischemic Stroke, Transient Ischemic Attack, Atherosclerotic Stenosis","enrollment":2873},{"nctId":"NCT01004406","phase":"PHASE3","title":"Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-09","conditions":"Acute Coronary Syndrome","enrollment":59},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT01221181","phase":"PHASE1","title":"Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-07","conditions":"Dense Deposit Disease, Membranoproliferative Glomerulonephritis","enrollment":6},{"nctId":"NCT03797339","phase":"","title":"Multi-omics Study of Clinical Endpoints in CHD","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-07-01","conditions":"Coronary Heart Disease","enrollment":4000},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT01954394","phase":"PHASE3","title":"Open Label Study of Long Term Safety Evaluation of Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-17","conditions":"Hypercholesterolemia","enrollment":986},{"nctId":"NCT03533959","phase":"","title":"To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2017-12-18","conditions":"Coronary Artery Disease Progression","enrollment":31},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02609256","phase":"NA","title":"Stereotactic Infarct Tissue Aspiration for Malignant Infarction of Middle Cerebral Artery","status":"TERMINATED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2015-12","conditions":"Middle Cerebral Artery Infarction","enrollment":12},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT01699126","phase":"PHASE4","title":"The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2010-05","conditions":"Sleep Apnea, Obstructive","enrollment":46},{"nctId":"NCT02707458","phase":"PHASE1, PHASE2","title":"Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration","status":"COMPLETED","sponsor":"Douglas Mental Health University Institute","startDate":"2016-04","conditions":"Dementia of the Alzheimer Type, Age-related Cognitive Decline, Mild Cognitive Impairment Due to Alzheimer Disease","enrollment":23},{"nctId":"NCT02354040","phase":"NA","title":"Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2015-04","conditions":"Vascular Disease, Cerebrovascular Disorders, Ischemic Heart Disease","enrollment":200},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT01760460","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03-14","conditions":"Dyslipidemia","enrollment":307},{"nctId":"NCT00125125","phase":"PHASE4","title":"Fluvastatin in Adults With Dislipidemia With History of Muscle Problems","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dyslipidemia","enrollment":218},{"nctId":"NCT02785874","phase":"NA","title":"Statin With Palliative Therapy for HCC","status":"TERMINATED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2016-09-01","conditions":"HCC","enrollment":4},{"nctId":"NCT01717300","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-06","conditions":"Hypercholesterolemia","enrollment":459},{"nctId":"NCT01703156","phase":"NA","title":"Low Risk Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2009-05","conditions":"Low Risk Acute Coronary Syndrome","enrollment":70},{"nctId":"NCT02363725","phase":"PHASE2","title":"Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2014-12","conditions":"Acute Myocardial Infarction","enrollment":44},{"nctId":"NCT03001635","phase":"PHASE2, PHASE3","title":"Role of Oxytocin in Myocardial Infarction","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-01","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01617655","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06","conditions":"Hypercholesterolaemia","enrollment":107},{"nctId":"NCT01824238","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":68},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT02008110","phase":"PHASE4","title":"Carbohydrate Antigen 125-guided Therapy in Heart Failure","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2011-12","conditions":"Heart Failure","enrollment":360},{"nctId":"NCT02037685","phase":"NA","title":"Improving Adherence to Statins Among Minority Populations","status":"COMPLETED","sponsor":"University of Miami","startDate":"2010-06","conditions":"Dyslipidemia","enrollment":779},{"nctId":"NCT01507831","phase":"PHASE3","title":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Hypercholesterolemia","enrollment":2341},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT00804843","phase":"PHASE2","title":"Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Carotid Atherosclerosis","enrollment":100},{"nctId":"NCT00554502","phase":"PHASE3","title":"Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2008-02","conditions":"IgA Nephropathy","enrollment":148},{"nctId":"NCT01389388","phase":"NA","title":"Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-01","conditions":"Carotid Artery Plaque, Ankylosing Spondylitis, Rheumatoid Arthritis","enrollment":114},{"nctId":"NCT01831037","phase":"","title":"The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2015-07","conditions":"Chronic Hepatitis C, Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01602913","phase":"","title":"Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12","conditions":"Depression, Postpartum","enrollment":1},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01200056","phase":"PHASE4","title":"Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment","status":"COMPLETED","sponsor":"Prof. Stephen Lee","startDate":"2007-08","conditions":"Coronary Disease, Ultrasonography, Interventional, Hydroxymethylglutaryl-CoA Reductase Inhibitors","enrollment":40},{"nctId":"NCT00323258","phase":"NA","title":"Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-06","conditions":"Cardiovascular Disease","enrollment":143}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"MYALGIA"},{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"BLOOD PRESSURE INADEQUATELY CONTROLLED"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CORONARY ARTERY STENOSIS"},{"count":1,"reaction":"DRUG DOSE OMISSION"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"FLUSHING"}],"_approvalHistory":[],"publicationCount":103,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Other Statin","genericName":"Other Statin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}